Comparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on a outpatient basis

Hematological Oncology

Volumn 29, Issue 3, 2011, Pages 139-143

  Ferrara, Felicetto ^a   Izzo, Tiziana ^a   Criscuolo, Clelia ^a   Riccardi, Cira ^a   Viola, Assunta ^a   Delia, Rossella ^a   Carbone, Antonella ^a   Celentano, Maria ^a  

^a CARDARELLI HOSPITAL   (Italy)

Author keywords

Autologous stem cell transplantation; Multiple myeloma; Outpatient; PEG filgrastim

Indexed keywords

ANTIBIOTIC AGENT; CD34 ANTIGEN; CEFTRIAXONE; CIPROFLOXACIN; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MORPHINE DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HOSPITAL READMISSION; HUMAN; INFECTION; LENGTH OF STAY; MALE; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEUTROPHIL COUNT; ORAL MUCOSITIS; OUTPATIENT; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; SEPTIC SHOCK; SINGLE DRUG DOSE; STOMATITIS; T LYMPHOCYTE; TOTAL PARENTERAL NUTRITION; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

AGED; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OUTPATIENTS; RECOMBINANT PROTEINS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 80052951952     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.978     Document Type: Article

References (19)

1. Gratwohl A, Baldomero H, Schwendener A, et al. The EBMT activity survey 2008 impact of team size, team density and new trends. Bone Marrow Transplant 2010. DOI: 10.1038/bmt.2010.69
2. Gratwohl A, Baldomero H, Aljurf M, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010; 303: 1617-1624.
3. Patriarca F, Petrucci MT, Bringhen S, et al. Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. Eur J Haematol 2009; 82: 93-105.
4. Palumbo A, Rajkumar SV. Multiple myeloma: chemotherapy or transplantation in the era of new drugs. Eur J Haematol 2010; 84: 379-390.
5. Bladé J, Rosiñol L, Cibeira MT, Rovira M, Carreras E. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010; 115: 3655-3663.
6. Harousseau JL. Hematopoietic stem cell transplantation in multiple myeloma. J Natl Compr Canc Netw 2009; 7: 961-970.
7. Harousseau JL, Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 2009; 360: 2645-2654.
8. Kumar S. Stem cell transplantation for multiple myeloma. Curr Opin Oncol 2009; 21: 162-170.
9. Morabito F, Martino M, Stelitano C, et al. Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma. Haematologica 2002; 87: 1192-1199.
10. Gertz MA, Ansell SM, Dingli D, et al. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc 2008; 83: 1131-1138.
11. Kassar M, Medoff E, Seropian S, Cooper DL. Outpatient high-dose melphalan in multiple myeloma patients. Transfusion 2007; 47: 115-119.
12. Zappasodi P, Nosari AM, Astori C, et al. DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients. Transfusion 2008; 48: 857-860.
13. Kobbe G, Bruns I, Fenk R, Czibere A, Haas R. Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT. Bone Marrow Transplant 2009; 43(9): 669-677.
14. Durie BG, Salmon S. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.
15. Laubach JP, Mitsiades CS, Mahindra A, et al. Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw 2009; 7: 947-960.
16. Jagannath S, Kyle RA, Palumbo A, Siegel DS, Cunningham S, Berenson J. The current status and future of multiple myeloma in the clinic. Clin Lymphoma Myeloma Leuk 2010; 10: 28-43.
17. Ferrara F, Palmieri S, Viola A, et al. Outpatient-based peripheral blood stem cell transplantation for patients with multiple myeloma. Hematol J 2004; 5: 222-226.
18. Musto P, Scalzulli PR, Terruzzi E, et al. Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature. Leuk Res 2007; 31: 1487-1493.
19. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 2004; 10: 1235-1244.